摘要
目的探讨小剂量阿糖胞苷和阿克拉霉素联合粒细胞集落刺激因子(G-CSF)治疗急性髓细胞白血病(AML)的疗效和不良反应。方法回顾性分析71例中位年龄65岁的AML患者,均采用CAG预激方案诱导治疗,为阿克拉霉素10 mg/d,第1～8天,阿糖胞苷10 mg/m2,12 h 1次,第1～14天,G-CSF 200μg/(m2·d),第1～14天。结果化疗后总有效率73.2%,完全缓解(CR)57.7%。初诊患者CR率为65.3%;复发、难治患者为40.9%;≥70岁患者为40%;中等预后染色体的CR率为68.4%。10例预后不良染色体异常的患者完全缓解4例。早期死亡率2.8%,总生存期中位时间14个月。初诊时白细胞<10×109/L的CR率61.1%,治疗前白细胞>10×109/L的CR率52.9%。化疗的不良反应主要为骨髓抑制,未见严重的非造血系统不良反应。结论 CAG预激方案为治疗AML的较有效、安全的方案。尤其对低增生性老年AML疗效肯定。
Objective To evaluate the efficacy and toxicity of low-dose cytarabine and aclarubicin in combination with G-CSF protocol in elderly patients with acute myeloid leukemia （AML）.Methods 71 patients were enrolled, the median age of 65 years,were treated with CAG regimen including aclarubicin （10 mg/d, days 1 to 8）, cytarabine （10 mg/m^2 per 12 h, days 1 to 14）, and G-CSF priming （200 μ g/m^2.d, days 1 to 14）. Results The overall response rate was 73.2%, and 57.7% patients achieved CR, 65.3% patients with previously untreated AML,40.9% patients with refractory, relapsed and secondary AML, 40.0% patients aged over 70 years, 40.0% patients with unfavourable cytogenetic aberrations.The early death rate was 2.8%.The median overall survival duration 14 months.Myelosuppression was mild to moderate,severe nonhematologic toxicity was not observed.Conclusion CAG priming regimen as the induction therapy is well tolerable and effective in elderly patients with AML.
出处
《湖南中医药大学学报》
CAS
2011年第2期26-28,共3页
Journal of Hunan University of Chinese Medicine
基金
江苏省卫生厅医学科研课题(编号H200703)
南京市医学科技发展项目(编号YKK08093)
